Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking method to diabetes management. These innovative drugs operate by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these agents boost insulin secretion and inhibit glucagon output

The management of diabetes continues to evolve with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant attention. These medications offer promising approaches for controlling blood sugar levels and potentially improve the lives of individuals living with diabetes